DECIPHERA PHARMACEUTICALS, INC. Financials Deciphera Pharmaceuticals, Inc.
Equities
DCPH
US24344T1016
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.65 USD | +3.31% |
|
-0.14% | -9.18% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,177 | 3,249 | 571.4 | 1,108 | 1,292 | 1,205 | - | - |
| Enterprise Value (EV) 1 | 2,597 | 2,697 | 484.3 | 1,043 | 1,212 | 891.9 | 987.5 | 958.2 |
| P/E ratio | -13.9 x | -11.9 x | -1.89 x | -6.92 x | -7.04 x | -6.79 x | -8.43 x | -16.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 127 x | 77.2 x | 5.94 x | 8.26 x | 7.91 x | 6.02 x | 4.62 x | 3.3 x |
| EV / Revenue | 104 x | 64.1 x | 5.04 x | 7.78 x | 7.42 x | 4.46 x | 3.79 x | 2.63 x |
| EV / EBITDA | -13 x | -10 x | -1.63 x | -5.8 x | -5.8 x | -4.41 x | -4.83 x | -5.29 x |
| EV / FCF | -16.8 x | -11 x | -1.99 x | -6.78 x | -8.22 x | -5.79 x | -7.11 x | -19.5 x |
| FCF Yield | -5.94% | -9.08% | -50.1% | -14.7% | -12.2% | -17.3% | -14.1% | -5.12% |
| Price to Book | 5.88 x | 6.05 x | 1.88 x | 3.62 x | 3.7 x | 4.05 x | 4.61 x | 5.18 x |
| Nbr of stocks (in thousands) | 51,044 | 56,933 | 58,481 | 67,576 | 80,123 | 82,226 | - | - |
| Reference price 2 | 62.24 | 57.07 | 9.770 | 16.39 | 16.13 | 14.65 | 14.65 | 14.65 |
| Announcement Date | 3/9/20 | 2/9/21 | 2/8/22 | 2/7/23 | 2/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 25 | 42.09 | 96.15 | 134 | 163.4 | 200 | 260.8 | 365 |
| EBITDA 1 | -199.9 | -268.9 | -297.1 | -179.8 | -208.9 | -202.3 | -204.5 | -181 |
| EBIT 1 | -200.7 | -271.2 | -300.1 | -182.7 | -211 | -205.8 | -183.1 | -129.8 |
| Operating Margin | -802.9% | -644.36% | -312.1% | -136.32% | -129.14% | -102.93% | -70.21% | -35.55% |
| Earnings before Tax (EBT) 1 | -192.3 | -266.5 | -300 | -178.2 | -194.5 | -185.8 | -162.5 | -84.43 |
| Net income 1 | -192.3 | -266.5 | -300 | -178.9 | -194.9 | -195 | -162.9 | -86.57 |
| Net margin | -769.02% | -633.19% | -311.98% | -133.49% | -119.34% | -97.51% | -62.44% | -23.72% |
| EPS 2 | -4.480 | -4.780 | -5.160 | -2.370 | -2.290 | -2.157 | -1.738 | -0.9049 |
| Free Cash Flow 1 | -154.2 | -245 | -242.8 | -153.7 | -147.5 | -154.1 | -138.8 | -49.05 |
| FCF margin | -616.92% | -582.13% | -252.52% | -114.67% | -90.28% | -77.05% | -53.22% | -13.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/20 | 2/9/21 | 2/8/22 | 2/7/23 | 2/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23.22 | 24.2 | 29.22 | 32.49 | 35.97 | 36.34 | 33.44 | 38.3 | 43.31 | 48.3 | 46.23 | 48.89 | 52.75 | 53.58 | 48.58 |
| EBITDA 1 | -78.91 | -87.62 | -46.11 | -42.97 | -44.14 | -46.56 | -52.65 | - | - | -50.78 | -50 | -49 | -50 | -53 | - |
| EBIT 1 | -79.67 | -88.4 | -46.89 | -43.79 | -44.88 | -47.16 | -53.26 | -52.78 | -53.69 | -51.24 | -51.4 | -51.61 | -50.91 | -51.94 | -48.59 |
| Operating Margin | -343.1% | -365.31% | -160.46% | -134.76% | -124.76% | -129.76% | -159.24% | -137.78% | -123.95% | -106.09% | -111.19% | -105.55% | -96.52% | -96.95% | -100% |
| Earnings before Tax (EBT) 1 | -79.84 | -88.4 | -46.89 | -43.06 | -43.04 | -45.23 | -49.61 | -48.56 | -49.58 | -46.76 | -47.52 | -46.92 | -46.02 | -47.33 | -44.11 |
| Net income 1 | -79.84 | -88.4 | -46.89 | -43.06 | -43.04 | -45.93 | -49.61 | -48.56 | -49.58 | -47.19 | -48.5 | -48.73 | -48.49 | -49.84 | -44.11 |
| Net margin | -343.83% | -365.28% | -160.46% | -132.52% | -119.65% | -126.38% | -148.33% | -126.78% | -114.47% | -97.71% | -104.91% | -99.65% | -91.93% | -93.02% | -90.79% |
| EPS 2 | -1.370 | -1.510 | -0.8000 | -0.6000 | -0.5500 | -0.6000 | -0.6000 | -0.5700 | -0.5800 | -0.5400 | -0.5474 | -0.5496 | -0.5166 | -0.5392 | -0.4600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/8/22 | 5/4/22 | 8/4/22 | 11/3/22 | 2/7/23 | 5/3/23 | 8/9/23 | 10/30/23 | 2/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 580 | 552 | 87.1 | 64.7 | 80 | 313 | 217 | 246 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -154 | -245 | -243 | -154 | -147 | -154 | -139 | -49.1 |
| ROE (net income / shareholders' equity) | -46.5% | -48.9% | -70.7% | -55.4% | -56.3% | -62.9% | -52.5% | -55% |
| ROA (Net income/ Total Assets) | -41% | -42.1% | -56% | -40.5% | -42% | -32.2% | -40.3% | -40% |
| Assets 1 | 469 | 632.4 | 536 | 441.8 | 463.8 | 605.8 | 404.2 | 216.6 |
| Book Value Per Share 2 | 10.60 | 9.440 | 5.200 | 4.530 | 4.360 | 3.620 | 3.180 | 2.830 |
| Cash Flow per Share | -3.480 | - | - | - | - | - | - | - |
| Capex 1 | 4.94 | 5.32 | 1.97 | 0.84 | 0.78 | 1.62 | 1.98 | 3.52 |
| Capex / Sales | 19.74% | 12.63% | 2.05% | 0.63% | 0.48% | 0.81% | 0.76% | 0.96% |
| Announcement Date | 3/9/20 | 2/9/21 | 2/8/22 | 2/7/23 | 2/6/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.65
USD
Average target price
24.2
USD
Spread / Average Target
+65.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.18% | 1.2B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- DCPH Stock
- Financials Deciphera Pharmaceuticals, Inc.
